Verona Pharma ( (VRNA) ) has released its Q3 earnings. Here is a breakdown of the information Verona Pharma presented to its investors.
Verona Pharma, a biopharmaceutical company focused on chronic respiratory diseases, has reported its third-quarter financial results for 2024, highlighting the successful launch of its COPD treatment, Ohtuvayre (ensifentrine), in the US market.
The company achieved net sales of $5.6 million for Ohtuvayre in the third quarter, with sales in October surpassing those figures, reflecting strong market adoption. The initial launch has seen over 5,000 prescriptions filled by more than 2,200 unique healthcare professionals, indicating broad acceptance of the therapy across various COPD patient types.
Verona Pharma is expanding its development pipeline, with two Phase 2 clinical trials underway. These trials include a dose-ranging study of a combination therapy involving glycopyrrolate for COPD maintenance and an investigation into ensifentrine’s efficacy in treating non-cystic fibrosis bronchiectasis. This continued focus on R&D is reflected in the company’s increased expenses in this area.
Despite the positive sales performance, Verona Pharma reported a net loss of $43 million for the quarter, driven by heightened R&D and SG&A expenses related to the product launch. The company’s cash position remains robust at $336 million, supported by strategic financings.
Looking ahead, Verona Pharma’s management is optimistic about the continued growth of Ohtuvayre sales and the advancement of its clinical trials, which are expected to bolster its position in the respiratory treatment market.
